Since September 2020, community pharmacists in France have been authorised to offer structured pharmaceutical care to adults receiving oral cancer drugs, and to bill the national health insurance system for providing this service.The main objectives of the programme are to help reduce the risk of adverse effects and promote treatment adherence. It remains to be clarified how this service will be coordinated between pharmacists and the other health professionals involved in the patients' care. As of 2021, community pharmacists in France and other countries are paid by national health systems to deliver other health care services in addition to dispensing drugs. These services include providing support to patients with chronic diseases, mainly to reduce the risk of adverse effects and drug interactions. For example, community pharmacists have been authorised since 2013 to arrange interviews with patients taking oral anticoagulants and adult asthma patients using an inhaled corticosteroid, and have been paid to offer this service. Since 2018, pharmacists have also been encouraged to conduct medication reviews with polymedicated patients over the age of 65 years, to evaluate all of the patient's treatments. These pharmaceutical care services are set out in a contract between the national health insurance system and representatives of the community pharmacy profession (1 ). The idea that pharmaceutical care contributes to the quality of health care has also acquired a legal basis at the European level, through a Council of Europe resolution (2).
展开▼
